ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > STEAP1

STEAP1

概要

Name:Six-transmembrane epithelial antigen of the prostate 1
Target Synonym:PRSS24,Six-transmembrane epithelial antigen of prostate 1,STEAP,STEAP1,STEAP Family Member 1,Six Transmembrane Epithelial Antigen Of The Prostate 1,STEAP1 Metalloreductase,Six Transmembrane Epithelial Antigen Of The Prostate,Metalloreductase STEAP1,EC 1.16.1.-,EC:1.16.1.-
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

CHEK-ATP154-Cell-based assay
 STEAP1 FACS

Fig. FACS analysis of STEAP1 on HEK293/Human STEAP1 Stable Cell Line.
FACS assay shows that Anti-STEAP1 antibody can bind to HEK293/Human STEAP1 Stable Cell Line. HEK293/Human STEAP1 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

SCCHO-ATP121-Cell-based assay
 STEAP1 FACS

Expression analysis of human STEAP1 on CHO/Human STEAP1 Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human STEAP1 Stable Cell Line or negative control cell using anti-human STEAP1 antibody followed by staining with PE anti-human IgG Fc Antibody.

ST1-H5283-SPR
 STEAP1 SPR

Anti-STEAP1 Antibody captured on Protein A Chip can bind Human STEAP1 Full Length Protein, Twin-Strep,His Tag (Cat. No. ST1-H5283) with an affinity constant of 2.95 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

ST1-H5283-ELISA
 STEAP1 ELISA

Immobilized Human STEAP1 Full Length Protein, Twin-Strep,His Tag (Cat. No. ST1-H5283) at 5 μg/mL (100 μL/well) on a Nickel Coated plate can bind Anti-STEAP1 Antibody with a linear range of 0.156-2.5 μg/mL (QC tested).

Synonym Name

STEAP1, PRSS24, STEAP

Background

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is an integral membrane protein that is highly up-regulated on the cell surface of several human cancers, making it a promising therapeutic target to manage these diseases. It shares sequence homology with three enzymes (STEAP2-STEAP4) that catalyze the NADPH-dependent reduction of iron(III). Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
89Zr-DFO-MSTP2109A Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Genentech Inc Prostatic Neoplasms Details
STEAP1 CART Cell Therapy(PromiCell) Phase 2 Clinical PromiCell Therapeutics Inc, Fred Hutchinson Cancer Research Center Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Xaluritamig AMG-509 Phase 1 Clinical Xencor Inc, Amgen Inc Prostatic Neoplasms, Castration-Resistant Details
ABBV-969 ABBV-969; ABBV969 Phase 1 Clinical Abbvie Inc, Immunogen Inc Prostatic Neoplasms, Castration-Resistant Details
89Zr-DFO-MSTP2109A Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Genentech Inc Prostatic Neoplasms Details
STEAP1 CART Cell Therapy(PromiCell) Phase 2 Clinical PromiCell Therapeutics Inc, Fred Hutchinson Cancer Research Center Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Xaluritamig AMG-509 Phase 1 Clinical Xencor Inc, Amgen Inc Prostatic Neoplasms, Castration-Resistant Details
ABBV-969 ABBV-969; ABBV969 Phase 1 Clinical Abbvie Inc, Immunogen Inc Prostatic Neoplasms, Castration-Resistant Details

This web search service is supported by Google Inc.

totopphone